Although the median age of the subjects in these trials was approximately 60 years, several elderly patients were included in these studies, and subset analysis of PFS showed a trend in favor of EGFR-TKI in the elderly group [ 21 – 23 ].
← all excerpts
Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.
1
—
—